AEGiS-Reuters: India Cannot Afford AIDS Medication

Reuters, Ltd.Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


India Cannot Afford AIDS Medication

Reuters NewMedia - Wednesday November 29, 2000


NEW DELHI (Reuters) - India cannot afford to care for all AIDS-affected people in the country because the treatment is too expensive for its health budget, a health ministry official said on Tuesday.

"Antiretroviral therapy given to people who are HIV-positive is beyond the reach of the Indian government because it costs $25,000 per patient per year," J. Rao, project director of the National AIDS Prevention and Control Organization, told an economic conference.

According to the United Nations, India has 3.7 million HIV-infected people, the largest number in the world after South Africa.

The official said the government had earmarked about $320 million for a 5-year project to counter the spread of the disease.

Rao said the cost of the therapy for the country's entire HIV-positive population was way above the government's total AIDS-control budget.He said India was hamstrung by the fact that it was heavily dependent on external funds from organisations like the United Nations to fight the disease.

Rao said the disease has become widespread in the Indian states of Maharashtra, Andhra Pradesh, Karnataka, Tamil Nadu, and the northeastern provinces of Nagaland and Manipur.

He added that Prime Minister Atal Behari Vajpayee, who had taken up the AIDS issue as a socioeconomic problem rather than just a health problem, was also trying to rope in industry to help combat the disease.

"The prime minister has launched an initiative with business leaders to promote AIDS awareness to the workplace and to provide care and support to infected workers," he said. ($1 - 46.88 rupees).
001129
RE001133


Copyright © 2000 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .